A revolution in the treatment and rehabilitation of muscle/tendon injuries is on its way with the development of a ground-breaking new intelligent technology developed at Griffith University and the University of Auckland.
Called iTraining, the biomedically engineered system works in real time to provide feedback on the stresses and strains that affect a specific muscle or tendon, either following injury or in the prevention of injury.
Following the award of a grant of nearly $1m from Australian Research Council and industry partners, Professor David Lloyd, from Griffith’s Menzies Health Institute Queensland, and other colleagues are now preparing to undertake a large three-part study that will focus on the Achilles tendon.
“Currently the mechanical environment of the Achilles tendon is poorly understood because of difficulties associated with directly measuring the stresses and strains experienced throughout the tendon in daily activities. If these issues can be overcome, it will be possible to identify the loading conditions required to facilitate favourable structural and mechanical adaption of healthy, as well as injured or diseased Achilles tendons,” says Professor Lloyd.
Potential to radically transform
“The technology to achieve this goal is now within reach and has the potential to radically transform the way athletic training and rehabilitation programs for the Achilles tendon are designed and monitored.
“The approach will allow the trainer to identify an individual’s optimal loading conditions for positive structural and mechanical adaption of their Achilles tendon, by using methods that integrate the necessary technologies to measure stress-strain of the tendon in real time.”
The study will be broken into three parts. Part A will aim to determine the optimal loading conditions required to alter the structural, mechanical and biochemical properties of the Achilles tendon; Part B will be to develop the iTraining system which will entail participants wearing next generation wearable sensors coupled with computer models, to provide real-time biofeedback of the tendon’s mechanical behaviour; Part C will determine the efficacy of an iTraining program to alter the structural properties of the human Achilles tendon.
Professor Lloyd says the iTraining approach will be likely to have broad application to other tendons and musculoskeletal tissues within the body.
“This new ‘intelligent’ approach to training and rehabilitation is at the forefront of modern developments in biomechanics, rehabilitation engineering, sports science and sports medicine.
“iTraining has the potential to radically transform the practice of exercise prescription across the full spectrum from elite performance to rehabilitation of acute and chronic musculoskeletal conditions,” he says.
“A key feature of this approach is that feedback is subject specific and therefore consistent with the concept of the ‘quantitative’ self and the trend in science and practice is of course, to move towards models of personalised medicine and rehabilitation.”
Professor Lloyd says he envisages that the technology could be available in public gyms and physiotherapy practices in as little as four years.
The Latest on: Personalised medicine
via Google News
The Latest on: Personalised medicine
- Nucleix's Non-Invasive Bladder EpiCheck™ Biomarker Test Allows for Personalized Monitoring of Bladder Cancer on February 21, 2019 at 9:30 am
"We strive to develop meaningful tools that can make a real impact on the practice of medicine and on patients. These findings demonstrate how using Bladder EpiCheck for personalized medicine can impr... […]
- Diagnostic Solutions Laboratory Revolutionizes Precision Medicine with GenomicInsight™ Genomic Health Profile Powered by Opus23 Explorer™ on February 21, 2019 at 4:00 am
ALPHARETTA, Ga., Feb. 21, 2019 /PRNewswire/ -- Diagnostic Solutions Laboratory (DSL) continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP tes... […]
- Personalized Medicines Account for 42% of All Drug Approvals in 2018 on February 20, 2019 at 2:31 pm
More than one-third of the therapies the FDA approved in the last 2 years includes information on the label identifying patients would benefit the most or experience fewer side effects, found a recent... […]
- QNRF and QGP launch third cycle of 'path towards personalized medicine' fund on February 20, 2019 at 5:50 am
Doha, Qatar: Qatar Genome Programme (QGP) and Qatar National Research Fund (QNRF), both members of Qatar Foundation, have launched the third cycle of the ‘Path Towards Personalized Medicine’ (PPM), a ... […]
- CareDx Drives Personalized Medicine in Transplantation at CEOT on February 20, 2019 at 5:00 am
BRISBANE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically ... […]
- Roche's personalised medicine, entrectinib receives US FDA priority review status on February 19, 2019 at 7:30 pm
Roche announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paedia... […]
- FDA grants Priority Review to Roche's personalised medicine entrectinib on February 19, 2019 at 3:47 am
Basel, 19 February 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company`s New Drug Applications (NDAs) and granted ... […]
- Microsoft and digital health: AI, IoT and cloud computing point the way to personalised care on February 19, 2019 at 3:00 am
Part of Healthcare NeXT, Microsoft's Genomics service and others like it could potentially help lay the foundations of a trend known as 'personalised medicine', one where treatment is targeted at the ... […]
- Nobel laureates to attend personalized medicine conference in Croatia on February 19, 2019 at 1:00 am
The International Society for Applied Biological Sciences (ISABS), the Mayo Clinic and St. Catherine Hospital have announced the 11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo C... […]
- FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib on February 18, 2019 at 10:21 pm
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and ... […]
via Bing News